Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort

Table 3 Association of baseline serum adipokine levels and radiographic disease progression defined as an increase of ≥1 in total SHS between inclusion and 1 year

		Univariate model		Model 1 “Base”		Model 2 “Metabolic”		Model 3 “Metabolic + RA”		Model 4 “Metabolic + RA + steroid”
		OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
Adiponectin	Total ∆SHS ≥1	1.34 (1.03-1.76)	0.03	1.59 (1.19-2.12)	0.002	1.57 (1.16-2.13)	0.004	1.84 (1.24-2.71)	0.002	1.84 (1.25-2.72)	0.002
	Erosive ∆SHS ≥1	1.34 (1.02-1.75)	0.03	1.56 (1.17-2.08)	0.003	1.54 (1.13-2.08)	0.006	1.73 (1.17-2.55)	0.006	1.73 (1.17-2.55)	0.006
	Narrowing ∆SHS ≥1	1.65 (1.05-2.61)	0.03	1.79 (1.10-2.90)	0.02	1.95 (1.16-3.27)	0.01	1.91 (1.04-3.52)	0.04	1.93 (1.04-3.57)	0.04
Leptin	Total ∆SHS ≥1	0.86 (0.71-1.05)	0.14	0.95 (0.76-1.18)	0.63	1.24 (0.9-1.70)	0.2	1.59 (1.05-2.41)	0.03	1.59 (1.05-2.42)	0.03
	Erosive ∆SHS ≥1	0.88 (0.72-1.07)	0.19	0.96 (0.77-1.20)	0.69	1.29 (0.93-1.78)	0.12	1.68 (1.11-2.56)	0.01	1.69 (1.11-2.57)	0.01
	Narrowing ∆SHS ≥1	0.93 (0.66-1.3)	0.66	0.93 (0.64-1.35)	0.70	1.09 (0.63-1.87)	0.76	1.1 (0.58-2.09)	0.76	1.10 (0.58-2.08)	0.77
Visfatin/NAMPT	Total ∆SHS ≥1	1.22 (0.99-1.51)	0.06	1.20 (0.97-1.49)	0.09	1.2 (0.95-1.49)	0.12	1.09 (0.81-1.46)	0.57	1.09 (0.81-1.46)	0.58
Visfatin/NAMPT	Erosive ∆SHS ≥1	1.25 (1.01-1.54)	0.04	1.23 (0.99-1.52)	0.06	1.22- (0.98-1.53)	0.08	1.14 (0.85-1.53)	0.37	1.14 (0.85-1.54)	0.37
	Narrowing ∆SHS ≥1	1.17 (0.82-1.67)	0.39	1.16 (0.81-1.67)	0.41	1.05 (0.73-1.53)	0.79	1.12 (0.72-1.75)	0.62	1.13 (0.72-1.77)	0.6

OR, odds ratio; 95% CI, 95% confidence interval. Total patient number, 530.
Data are unadjusted and adjusted odds ratios with p values. Bold P values are significant.
Radiographic progression is defined as variation in total SHS between inclusion and 1 year (total ∆SHS) ≥1.
Erosive radiographic progression is defined as variation in erosive SHS between inclusion and 1 year (erosive ∆SHS ≥1).
Narrowing radiographic progression is defined as variation in narrowing SHS between inclusion and 1 year (narrowing ∆SHS ≥1).
Multivariate models:
Model 1 (“base”): sex + age (n = 530).
Model 2 (“metabolic”): Model 1 + BMI + HOMA-IR index (n = 497).
Model 3 (“metabolic + RA”): Model 2 + CRP level + DAS28-ESR value + HAQ score + RF status + anti-CCP antibody status + presence of radiographic changes at inclusion (n = 344).
Model 4 (“metabolic + RA + steroid”): Model 3 + steroid prescription at inclusion (n = 344).
The following variables were log-transformed: CRP level, HAQ score, serum adipokine levels.

ISSN: 1478-6362